In short
This article provides information about 2 ongoing clinical trials investigating treatments for hyperthyroidism, a condition where the thyroid gland becomes overactive and produces too much thyroid hormone. These trials are exploring different treatment approaches including radiofrequency ablation, radioactive iodine therapy, and iodine solution for patients with overactive thyroid nodules and Graves' disease.
Clinical trial locations
- Netherlands
- Sweden
Study Comparing Radiofrequency Ablation and Sodium Iodide (131I) for Treating Hyperthyroidism in Patients with Overactive Thyroid Nodules
This trial, conducted in the Netherlands, is comparing two different treatment approaches for patients whose hyperthyroidism is caused by solitary autonomous thyroid nodules. These are single lumps in the thyroid gland that produce too much thyroid hormone on their own, causing the symptoms of an overactive thyroid.
Main focus: The study aims to compare ultrasound-guided radiofrequency ablation with radioactive iodine therapy over a one-year period. Researchers are particularly interested in monitoring the occurrence of irreversible hypothyroidism, where the thyroid becomes permanently underactive after treatment. The trial will also track thyroid function, nodule size, quality of life, and overall health outcomes at regular intervals throughout the year.
Inclusion criteria: To participate in this study, you must be older than 18 years and have hyperthyroidism or subclinical hyperthyroidism caused by a single overactive thyroid nodule. This diagnosis must be confirmed through blood tests showing low TSH levels with normal or high FT4 and FT3 levels, negative anti-TSH antibodies, and a special scan using I-123 or I-131 that matches a clearly defined nodule on ultrasound. The nodule should be smaller than 50 mm and have less than 75% fluid-filled areas. You must be eligible for both radioactive iodine treatment and radiofrequency ablation, and you must sign an informed consent form.
Exclusion criteria: You cannot participate if you have a history of hyperactive thyroid nodules. The study excludes individuals considered part of vulnerable populations, such as children, pregnant women, or those unable to give consent. Specific age restrictions apply, though the exact upper limit is not specified beyond being over 18.
Investigational treatments: The trial uses two approaches. Radiofrequency ablation uses heat generated by radio waves to destroy the abnormal thyroid tissue, guided by ultrasound to precisely target the nodule. Radioactive iodine involves taking sodium iodide (131I) orally in capsule form, at doses ranging from 0.329 to 3.7 MBq, which is absorbed by the thyroid gland and gradually destroys the overactive cells.
Study on Preoperative Aqueous Iodine Solution for Patients with Hyperthyroidism Due to Graves' Disease and Toxic Nodular Goiter
This Swedish trial is investigating the use of Lugol's solution, an iodine-containing solution, in patients with hyperthyroidism caused by either Graves' disease or toxic nodular goiter. The study is particularly focused on whether this treatment can be safely used before thyroid surgery and whether it can reduce certain surgical complications.
Main focus: The trial is divided into two parts. The pilot study examines how safely Lugol's solution can be used in patients with toxic nodular goiter and monitors its effects on thyroid hormone levels and heart rate over 10 days. The main study investigates whether using this iodine solution before thyroid surgery can reduce the risk of temporary hypoparathyroidism, a condition where the parathyroid glands temporarily stop working properly after surgery. The study also evaluates quality of life, permanent hypoparathyroidism, and any problems with the nerves that control the voice.
Inclusion criteria: You can participate if you are between 18 and 75 years old and have been diagnosed with hyperthyroidism due to toxic nodular goiter or Graves' disease. You must be accepted for a thyroidectomy, which is surgery to remove all or part of the thyroid gland. Both men and women can participate.
Exclusion criteria: You cannot join this study if you are pregnant or breastfeeding. People with severe heart problems, kidney disease affecting kidney function, or a history of allergic reactions to iodine are excluded. You also cannot participate if you have had recent thyroid surgery, are currently taking medications that affect thyroid function, have other serious health conditions that might interfere with the study, or are unable to follow study procedures or attend follow-up visits.
Investigational treatment: Lugol's Solution is an iodine solution taken orally over a 10-day period before surgery. The solution works by providing iodine, which helps decrease the production of thyroid hormones by the thyroid gland. Throughout the treatment period, researchers will monitor thyroid hormone levels including TSH, fT4, and fT3, as well as heart rate on days 0, 3-4, 6-7, and 10.
Summary
These two clinical trials represent current research efforts to improve treatment options for different forms of hyperthyroidism. The Netherlands trial focuses on comparing two established treatment methods for solitary thyroid nodules, while the Swedish study explores a preoperative preparation approach for patients scheduled for thyroid surgery.
Both trials demonstrate the ongoing work to refine treatment strategies, reduce complications, and improve quality of life for patients with hyperthyroidism. The Netherlands study offers participants access to radiofrequency ablation, which is gaining recognition as an alternative to traditional radioactive iodine therapy. The Swedish trial investigates a relatively simple intervention that could potentially reduce surgical complications.
Patients interested in participating should discuss these trials with their healthcare providers to determine if they meet the eligibility criteria and whether participation would be appropriate for their individual circumstances.
